# R-5780

Source: https://onco.cc/drugs/r-5780/  
OnCo record `r-5780` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

R-5780 is an experimental pill from Rise Therapeutics designed to help immunotherapy drugs work in tumours that resist them. It is in an early trial with PD-1 inhibitors.

## Summary

R-5780 is an oral immunotherapy developed by Rise Therapeutics to enhance immune checkpoint inhibitor activity in tumours refractory to them or classically unresponsive. It is being tested in a phase 1 trial with PD-1 inhibitors in patients with solid tumours (NCT06398418), sponsored by Rise. No results have been published.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Also known as: R-5780-01
- Tags: pipeline
- Code: R-5780
- Modality: Oral microbial immunotherapy
- Mechanism: Delivers secreted antigen A (SagA) from Enterococcus faecium to engage microbiome-associated pattern recognition receptors in the gut and potentiate PD-1 and CTLA-4 blockade, as the developer's award abstract describes.

## Sources

- ClinicalTrials.gov: NCT06398418: https://clinicaltrials.gov/study/NCT06398418
- Rise Therapeutics: pipeline: https://risetherapeutics.com/pipeline/

## Connected records

- technologies: [Microbiome modulation to unlock immunotherapy](https://onco.cc/technologies/microbiome-modulation-io/)
- companies: [Rise Therapeutics](https://onco.cc/companies/rise-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/r-5780.json